Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-02

FDA Approved: NEBIVOLOL — Supplemental Application (Solco Healthcare US, LLC)

View source ↗

Summary

The FDA approved a supplemental application for Nebivolol from Solco Healthcare US, LLC, enabling a generic Nebivolol product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Nebivolol (Nebivolol)

Snippet

SUPPL AP for NEBIVOLOL (NEBIVOLOL)